SB5 investigational biosimilar candidate to Humira ? ( adalimumab ) : On November 10 , 2015 at the ACR ARHP Annual Meeting in San Francisco , Samsung Bioepis announced 24 week Phase 3 clinical study results that showed comparable safety and equivalent efficacy to Humira ? , as evidenced in ACR20 response rate of 72 . 5 in the SB5 arm versus 72 . 0 in the Humira ? arm . The study randomized 544 patients with moderate to severe rheumatoid arthritis despite methotrexate therapy across 52 sites in seven countries .
